Provided By GlobeNewswire
Last update: Nov 6, 2024
JERSEY CITY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2024.
Read more at globenewswire.comNASDAQ:SCYX (3/7/2025, 8:00:02 PM)
0.9677
+0.01 (+0.8%)
Find more stocks in the Stock Screener